RBC Capital analyst Lisa Walter reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report) today and set a price target of $39.00. The company’s shares opened today at $6.09.

4D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and Degeneration meeting, and while there was some ...

Trolling 101 Snap CEO Evan Spiegel has taken a public jab at Mark Zuckerberg and Meta, updating his LinkedIn profile with an unexpected addition to his job titles. Alongside "loving husband and ...

Ram Charan is all set for his upcoming film titled RC16 (tentatively). Directed by Buchi Babu Sana, the movie also features Janhvi Kapoor. Recently, Ram Charan set the internet on fire with a ...

Speaking to reporters on Friday, John Tortorella said he wasn’t worried about the Flyers getting up to play their last game before the 4 Nations Face-Off break. After all, the team was on a five-game ...